CARDIOKINE BIOPHARMA™ provides scientific research and development of pharmaceutical products in the cardiovascular therapeutic area. One such product is lixivaptan. Together with our world wide partner, Biogen Idec, the development of this compound will include its evaluation in hyponatremia and significant co-morbid conditions in the cardiovascular arena.

Cardiokine is dedicated to addressing unmet needs in cardiovascular medicine, and our initial focus is on congestive heart failure.

Hyponatremia is the most common electrolyte disorder and is especially prevalent in hospitalized patients with congestive heart failure, as well as in patients with cirrhosis and SIADH (syndrome of inappropriate anti-diuretic hormone). Hyponatremia affects as many as 7.5 million U.S. hospital patients, including more than 1 million heart failure patients, and is recognized as an independent contributor to negative patient outcomes in many chronic diseases.

Our lead compound is lixivaptan for patients suffering from hyponatremia, low levels of sodium and other electrolytes. Lixivaptan may help some patients eliminate excess fluid while retaining electrolytes.